Table 2.

Changes in inflammatory markers, markers of mineral metabolism, bone markers, serum calcification propensity, and kidney function during control and treatment periods

VariableControlSodium Bicarbonate TreatmentDifference in Change Estimate (95% CI), P Value
Baseline Value6 wkP ValueBaseline Value6 wkP Value
Bicarbonate, mEq/L19.7±2.319.6±3.20.9319.3±2.922.0±3.1<0.0012.7 (0.9 to 4.6), <0.01
hs-CRP, mg/dl3.2 (1.0–8.6)1.9 (1.0–16.0)0.372.7 (1.3–4.8)4.6 (1.3–9.4)0.150.2 (−0.4 to 0.9), 0.47
IL-6, mg/dl8.3 (3.8–11.2)8.0 (4.6–21.3)0.227.0 (4.4–9.2)7.3 (4.7–11.2)0.76−0.2 (−0.4 to 0.05), 0.11
Calcium, mg/dl9.4±0.49.2±0.50.139.2±0.59.3±0.50.390.2 (0.02 to 0.05), 0.03
Phosphorus, mg/dl4.2±0.84.2±1.10.854.1±0.64.5±1.10.020.4 (0.03 to 0.8), 0.04
Intact parathyroid hormone, pg/ml135 (72–266)149 (68–251)0.91138 (86–251)167 (101–385)0.130.003 (−0.3 to 0.3), 0.89
iFGF23, pg/ml240 (142–465)210 (171–678)0.68228 (150–362)257 (176–832)0.030.3 (−0.02 to 0.5), 0.06
T50, min280±45275±340.64233±58225±940.77−3.1 (−52.4 to 45.3), 0.90
C-telopeptide, ng/ml1.1±0.71.2±0.60.121.1±0.71.3±0.90.200.02 (−0.2 to 0.3), 0.87
Procollagen type 1 N propeptide, ng/ml81±4473±340.7473±3376±460.129.0 (−5.9 to 24.0), 0.23
GFR, ml/min per 1.73 m224±823±90.4225±823±100.12−0.9 (−4.2 to 2.3), 0.54
  • Values are expressed as mean±SD or median (interquartile range). To examine whether treatment by sodium bicarbonate has effect on these secondary outcomes, a study with crossover design was conducted and a mixed effects model was employed in data analysis. The P values were from the mixed effects model in testing the null hypothesis that the treatment does not have effect on any of the secondary outcomes. 95% CI, 95% confidence interval; hs-CRP, high-sensitivity C-reactive protein; iFGF23, intact fibroblast growth factor 23.